Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.

Lung cancer (Amsterdam, Netherlands) - 1 May 2010

Onitsuka Takamitsu, Uramoto Hidetaka, Nose Naohiro, Takenoyama Mitsuhiro, Hanagiri Takeshi, Sugio Kenji, Yasumoto Kosei

Abstract excerpt

BACKGROUND: Some types of somatic mutation of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC) are associated with a significant clinical response to a tyrosine kinase inhibitor (TKI). However, most of the patients with this type of sensitive mutations in their tumor show acquired resistance during the TKI treatment. METHODS: The mutations in exons 19-21 of the EGFR gene were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Disease Progression

Share to DNA Mutational Analysis

Share to Lung Neoplasms

Share to Mutation

Share to Prognosis

Source

Identifiers

PMID: 19589612
DOI: 10.1016/j.lungcan.2009.05.022

Genes

EGFR
HGF
MET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.PMID 19589612Read ↗

Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.Semantic proximity Read ↗

T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.Semantic proximity Read ↗

Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer.Semantic proximity Read ↗

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.Semantic proximity Read ↗

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase DomainSemantic proximity Read ↗

Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment StrategySemantic proximity Read ↗

Analysis of <i>Epidermal Growth Factor Receptor</i> Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to GefitinibSemantic proximity Read ↗

Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatment.Semantic proximity Read ↗

Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.Semantic proximity Read ↗

Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.Semantic proximity Read ↗

Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.Semantic proximity Read ↗

Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.